Ranolazine is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina.
Contact Information
9 Squares Building, Monalisha Township
Near Zanzarda Chowkdi, Junagadh 362001 (Gujrat, India)
Structure
Product Description
| Details | |
|---|---|
| Chemical Name | RANOLAZINE |
| IUPAC Name | (RS)-N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)-propyl]piperazin-1-yl]acetamide |
| CAS Number | 142387-99-3 |
| Molecular Formula | C24H33N3O4 |
| Synonyms | RANOLAZINE;n-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide;1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethy]piperazine;CVT 303;Ranexa;Renexa;RS 43285-003;1-Piperazineacetamide,N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]- |
| Application | For the treatment of chronic angina. It should be used in combination with amlodipine, beta-blockers or nitrates. |